ELAN:NYSE
Elanco Animal Health Inc
$22.92
arrow_upward
+1.69%(+0.38) 1D
$22.92
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 9, 4:00:06 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ELAN...
Open
$22.59
High
$22.98
Low
$22.42
Mkt. cap
11.45B
Avg. vol.
5.41M
Volume
2.52M
52-wk high
$27.98
52-wk low
$19.40
EPS
-$0.42
Beta
1.71
Shares outstanding
499.62M
No. of employees
10K
Open
$22.59
High
$22.98
Low
$22.42
Mkt. cap
11.45B
Avg. vol.
5.41M
Volume
2.52M
52-wk high
$27.98
52-wk low
$19.40
EPS
-$0.42
Beta
1.71
Shares outstanding
499.62M
No. of employees
10K
News stories
From web sources and news partners
AD HOC NEWS
·
2 days ago
Elanco stock costs EUR 19.85 ahead of third-quarter results
Profile
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world. Wikipedia
About Elanco Animal Health Inc
CEOJeffrey N. Simmons
Employees9.65K
Founded1954
HeadquartersIndianapolis, Indiana, United States
SectorPharmaceutical industry
Websiteelanco.com
Analyst ratings
Based on 12 analysts giving stock ratings to ELAN in the past 3 months
Strong buy
Buy
11
Hold
1
Sell
0
12-month forecast
Based on 12 Wall Street analysts offering 12 month price targets for ELAN in the last 3 months.
Highest
Current $22.92
$34.00 (+48.34%)
Average
$31.44 (+37.17%)
Lowest
$26.00 (+13.44%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Daniel Clark Leerink Partners | Buy | Reiterated | $34.00 | +48.3% | 10/01/2026 |
Jonathan Block Stifel Nicolaus | Buy | Reiterated | - | - | 09/18/2026 |
Steve Scala TD Cowen | Buy | Reiterated | $32.00 | +39.6% | 08/25/2026 |
Glen Santangelo Barclays | Buy | Maintained | $30.00 | +30.9% | 08/21/2026 |
Michael Ryskin Bank of America Securities | Buy | Maintained | $34.00 | +48.3% | 08/12/2026 |
Brandon Vazquez William Blair | Buy | Maintained | - | - | 08/12/2026 |
Chris Schott J.P. Morgan | Buy | Maintained | - | - | 08/11/2026 |
Erin Wright Morgan Stanley | Hold | Reiterated | $26.00 | +13.4% | 08/10/2026 |
David Westenberg Piper Sandler | Buy | Maintained | $30.00 | +30.9% | 08/10/2026 |
Andrea Alfonso UBS | Buy | Maintained | $33.00 | +44% | 08/06/2026 |
Daniel Grosslight Citi | Buy | Maintained | $34.00 | +48.3% | 08/06/2026 |
Scott Schoenhaus KeyBanc | Buy | Maintained | $30.00 | +30.9% | 08/06/2026 |
Jasper Hellweg Argus Research | Buy | Maintained | - | - | 06/23/2026 |
Umer Raffat Evercore ISI | Buy | Maintained | - | - | 05/11/2026 |
Unknown Analyst Jefferies | Buy | Maintained | $30.00 | +30.9% | 02/25/2026 |
Last report
Aug 5, 2026
Fiscal period
Q2 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$0.34 / $0.27
+26.46%beat
arrow_upward
Revenue / Est. (USD)
1.37B / 1.31B
+4.16%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.14B | 1.14B | 1.37B | 1.37B |
Cost of goods sold | 530.00M | 555.00M | 586.00M | 570.00M |
Cost of revenue | 530.00M | 555.00M | 586.00M | 570.00M |
Research and development expenses | 89.00M | 93.00M | 97.00M | 92.00M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 351.00M | 331.00M | 381.00M | 449.00M |
Operating expense | 580.00M | 563.00M | 616.00M | 680.00M |
Total operating expenses | 1.11B | 1.12B | 1.20B | 1.25B |
Operating income | 27.00M | 26.00M | 169.00M | 118.00M |
Other non operating income | 2.00M | -15.00M | -8.00M | -11.00M |
EBT including unusual items | -50.00M | -259.00M | 87.00M | 56.00M |
EBT excluding unusual items | -25.00M | -37.00M | 103.00M | 65.00M |
Income tax expense | -16.00M | 17.00M | 30.00M | 2.00M |
Effective tax rate | 32.00% | -6.56% | 34.48% | 3.57% |
Other operating expenses | - | - | - | - |
Net income | -34.00M | -276.00M | 57.00M | 54.00M |
Net profit margin | -2.99% | -24.13% | 4.16% | 3.95% |
Earnings per share | 0.19 | 0.13 | 0.40 | 0.34 |
Interest and investment income | - | 45.00M | - | - |
Interest expense | -52.00M | -105.00M | -57.00M | -59.00M |
Net interest expenses | -52.00M | -60.00M | -57.00M | -59.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 195.00M | 194.00M | 335.00M | 283.00M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1